Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan;53(1):194-195.
doi: 10.1111/apt.16159.

Editorial: anti-drug antibodies and the benefit of assay validation

Robert Little  1 , Miles P Sparrow  1
Affiliations
Editorial

Editorial: anti-drug antibodies and the benefit of assay validation

Robert Little et al. Aliment Pharmacol Ther. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655-1668.
    1. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
    1. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827-834.
    1. Nice R, Chanchlani N, Green H, et al. Validating the positivity thresholds of drug- tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther. 2020;53:128-137.
    1. Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341-353.

LinkOut - more resources